Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Abstract Background Clinical management of skin-toxicity associated with the use of anti-Epidermal Growth Factor Receptor (EGFR) antibodies to treat colorectal cancer maintains quality of life of patients with colorectal cancer. Results of clinical trials have recommended the efficacy of prophylacti...

Full description

Bibliographic Details
Main Authors:	Munenobu Kashiwa, Ryo Matsushita
Format:	Article
Language:	English
Published:	BMC 2021-10-01
Series:	Journal of Pharmaceutical Health Care and Sciences
Subjects:	Panitumumab Skin-toxicity Cost-effectiveness Colorectal cancer
Online Access:	https://doi.org/10.1186/s40780-021-00218-7

Similar Items

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01)

Patient considerations in metastatic colorectal cancer – role of panitumumab
by: Rogers JE
Published: (2017-04-01)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler Josef, et al.
Published: (2012-09-01)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
by: Battaglin F, et al.
Published: (2019-06-01)

Second-line panitumumab as a triweekly dose for patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer: a single-institution experience
by: Mohamed A. Daoud, et al.
Published: (2016-03-01)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
by: Francesca Battaglin, et al.
Published: (2018-01-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
by: Ho Wai Derrick Siu, et al.
Published: (2021-08-01)

STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
by: V. A. Gorbunova
Published: (2015-05-01)

OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
by: L. V. Bolotina
Published: (2015-02-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
by: Tetsuji Terazawa, et al.
Published: (2019-06-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
by: Jiang W, et al.
Published: (2018-07-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
by: Vogel Arndt, et al.
Published: (2018-05-01)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
by: Buchler T, et al.
Published: (2018-12-01)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
by: Tang XM, et al.
Published: (2017-12-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
by: Kimberly A. Lowe, et al.
Published: (2019-05-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
by: Maria Debora De Pasquale, et al.
Published: (2020-02-01)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
by: Ankur Bahl, et al.
Published: (2020-06-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report
by: Atsushi Kawasaki, et al.
Published: (2013-05-01)

Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
by: Esther Kim, et al.
Published: (2019-07-01)

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
by: Françoso A, et al.
Published: (2017-01-01)

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study
by: M. Yu. Fedyanin, et al.
Published: (2019-06-01)

Panitumumab-associated encephalopathy after accidental intra-arterial application through dislocated Port-a-Cath device in the left ventricle
by: Slaven Pikija, et al.
Published: (2016-11-01)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
by: Valeria Internò, et al.
Published: (2020-09-01)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)